Biologics register for rheumatoid arthritis

Tracking progress of patients with severe RA who are receiving biologic agents, to monitor safety and effectiveness over the long-term.


The society's RA register has been in operation for more than 18 years and is run by an expert team based in the Versus Arthritis Epidemiology Unit at the University of Manchester. The register monitors the safety and effectiveness of biologic treatments and captures information about adverse events.

Patients on the register are flagged with the NHS Information Centre, which notifies the register of anyone who develops cancer plus any deaths, with their cause.

Patients with similar disease activity on conventional disease-modifying anti-rheumatic drugs and recruited in a cohort since closed still provide comparison data. The register is on the NIHR CLRN portfolio database, so there is financial support for registering patients.

Now recruiting for:

  • Amgevita

  • Benepali

  • Cimzia

  • Enbrel

  • Erelzi

  • Flixabi

  • Humira

  • Imraldi

  • Inflectra

  • Kevzara

  • Olumiant

  • Remsima

  • Remicade

  • Rixathon

  • RoActemra

  • Xeljanz

If you are an NHS clinician, health professional or research network staff with a recruitment query about a patient or the treatment cohorts in rheumatoid arthritis please get in touch below.

Visit study website


View study

Submit an enquiry


 Submit enquiry